Cytokines and chemokines as regulators of skeletal muscle inflammation: Presenting the case of Duchenne muscular dystrophy

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  De Paepe, Boel ^a   De Bleecker, Jan L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CYTOKINE; DYSTROPHIN; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSTATIN; RANTES; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; INTERFERON; INTERLEUKIN DERIVATIVE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CYTOKINE RELEASE; DERMATOMYOSITIS; DNA FRAGMENTATION; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL CAT; EXPERIMENTAL DOG; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INCLUSION BODY MYOSITIS; MACROPHAGE; MOUSE MODEL; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; MYOSITIS; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOP CODON; UPREGULATION; ZEBRA FISH; ANIMAL; CELL ADHESION; DISEASE MODEL; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; INFLAMMATION; METABOLISM; MOUSE; REVIEW;

ANIMALIA;

ANIMALS; CELL ADHESION; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INTERFERONS; INTERLEUKINS; MICE; MUSCULAR DYSTROPHY, DUCHENNE; TRANSFORMING GROWTH FACTORS; TUMOR NECROSIS FACTORS;

EID: 84889053872     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/540370     Document Type: Article

References (84)

1. Deconinck N., Dan B., Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatric Neurology 2007 36 1 1 7 2-s2.0-33947258069 10.1016/j.pediatrneurol.2006.09.016
2. Petrof B. J., Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. American Journal of Physical Medicine and Rehabilitation 2002 81 11 S162 S174 2-s2.0-0036839039 10.1097/00002060-200211001-00017
3. McDouall R. M., Dunn M. J., Dubowitz V., Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. Journal of the Neurological Sciences 1990 99 2-3 199 217 2-s2.0-0025081106
4. Mantegazza R., Andreetta F., Bernasconi P., Baggi F., Oksenberg J. R., Simoncini O., Mora M., Cornelio F., Steinman L., Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V α / β rearrangements may indicate antigen-driven selection. Journal of Clinical Investigation 1993 91 6 2880 2886 2-s2.0-0027272073
5. Morrison J., Lu Q. L., Pastoret C., Partridge T., Bou-Gharios G., T-cell-dependent fibrosis in the mdx dystrophic mouse. Laboratory Investigation 2000 80 6 881 891 2-s2.0-0033918282
6. Morrison J., Palmer D. B., Cobbold S., Partridge T., Bou-Gharios G., Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. American Journal of Pathology 2005 166 6 1701 1710 2-s2.0-19544374647
7. Middleton J., Patterson A. M., Gardner L., Schmutz C., Ashton B. A., Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002 100 12 3853 3860 2-s2.0-0036892646 10.1182/blood.V100. 12.3853
8. Sharp N. J. H., Kornegay J. N., Van Camp S. D., Herbstreith M. H., Secore S. L., Kettle S., Hung W.-Y., Constantinou C. D., Dykstra M. J., Roses A. D., Bartlett R. J., An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992 13 1 115 121 2-s2.0-0026538578 10.1016/0888-7543(92)90210-J
9. Gaschen F., Burgunder J.-M., Changes of skeletal muscle in young dystrophin-deficient cats: a morphological and morphometric study. Acta Neuropathologica 2001 101 6 591 600 2-s2.0-0034920993
10. Bassett D. I., Currie P. D., The zebrafish as a model for muscular dystrophy and congenital myopathy. Human Molecular Genetics 2003 12 2 R265 R270 2-s2.0-0141925699
11. Kawahara G., Karpf J. A., Myers J. A., Alexander M. S., Guyone J. R., Kunkel L. M., Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America 2011 108 13 5331 5336 2-s2.0-79955100665 10.1073/pnas.1102116108
12. Lundberg I., Brengman J. M., Engel A. G., Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. Journal of Neuroimmunology 1995 63 1 9 16 2-s2.0-0028807858 10.1016/0165-5728(95)00122-0
13. Tidball J. G., Wehling-Henricks M., Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Current Opinion in Rheumatology 2005 17 6 707 713 2-s2.0-27544457274 10.1097/01.bor.0000179948.65895.1a
14. Porreca E., Guglielmi M. D., Uncini A., Gregorio P. D., Angelini A., Febbo C. D., Pierdomenico S. D., Baccante G., Cuccurullo F., Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thrombosis and Haemostasis 1999 81 4 543 546 2-s2.0-0032929087
15. Saito K., Kobayashi D., Komatsu M., Yajima T., Yagihashi A., Ishikawa Y., Minami R., Watanabe N., A sensitive assay of tumor necrosis factor α in sera from Duchenne muscular dystrophy patients. Clinical Chemistry 2000 46 10 1703 1704 2-s2.0-0033775805
16. Abdel-Salam E., Abdel-Meguid I., Korraa S. S., Markers of degeneration and regeneration in Duchenne muscular dystrophy. Acta Myologica 2009 28 3 94 100 2-s2.0-77951781389
17. Tews D. S., Goebel H. H., Cytokine expression profile in idiopathic inflammatory myopathies. Journal of Neuropathology and Experimental Neurology 1996 55 3 342 347 2-s2.0-0029866744
18. Kuru S., Inukai A., Kato T., Liang Y., Kimura S., Sobue G., Expression of tumor necrosis factor- α in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathologica 2003 105 3 217 224 2-s2.0-0038113417
19. Kumar A., Boriek A. M., Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB Journal 2003 17 3 386 396 2-s2.0-0037336186 10.1096/fj.02-0542com
20. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., Mornet D., L-arginine decreases inflammation and modulates the nuclear factor- B/matrix metalloproteinase cascade in mdx muscle fibers. American Journal of Pathology 2008 172 6 1509 1519 2-s2.0-44849127317 10.2353/ajpath.2008.071009
21. Spencer M. J., Marino M. W., Winckler W. M., Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscular Disorders 2000 10 8 612 619 2-s2.0-0033787688 10.1016/S0960-8966(00)00160-7
22. Creus K. K., De Paepe B., Weis J., De Bleecker J. L., The multifaceted character of lymphotoxin β in inflammatory myopathies and muscular dystrophies. Neuromuscular Disorders 2012 22 8 712 719 10.1016/j.nmd.2012.04.012
23. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular Cell Biology 2010 11 10 700 714 2-s2.0-77957105977 10.1038/nrm2970
24. Tidball J. G., Albrecht D. E., Lokensgard B. E., Spencer M. J., Apoptosis precedes necrosis of dystrophin-deficient muscle. Journal of Cell Science 1995 108 6 2197 2204 2-s2.0-0029034975
25. Serdarolu A., Gücüyener K., Erdem S., Köse G., Tan E., Okuyaz Ç., Role of apoptosis in Duchenne's muscular dystrophy. Journal of Child Neurology 2002 17 1 66 68 2-s2.0-0036117721
26. Kondo M., Murakawa Y., Harashima N., Kobayashi S., Yamaguchi S., Harada M., Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology 2009 128 1 e589 e599 2-s2.0-68249146074 10.1111/j.1365-2567.2008.03039.x
27. Behrens L., Bender A., Johnson M. A., Hohlfeld R., Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997 120 6 929 938 2-s2.0-0030918667 10.1093/brain/120.6.929
28. De Bleecker J. L., Meire V. I., Van Walleghem I. E., Groessens I. M., Schröder J. M., Immunolocalization of Fas and Fas ligand in inflammatory myopathies. Acta Neuropathologica 2001 101 6 572 578 2-s2.0-0034920990
29. Dogra C., Changotra H., Mohan S., Kumar A., Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor- B and degradation of MyoD protein. Journal of Biological Chemistry 2006 281 15 10327 10336 2-s2.0-33744542153 10.1074/jbc.M511131200
30. Mittal A., Bhatnagar S., Kumar A., Paul P. K., Kuang S., Kumar A., Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. American Journal of Pathology 2010 177 4 1732 1742 2-s2.0-77957338124 10.2353/ajpath.2010.100335
31. Rufo A., Del Fattore A., Capulli M., Carvello F., De Pasquale L., Ferrari S., Pierroz D., Morandi L., De Simone M., Rucci N., Bertini E., Bianchi M. L., De Benedetti F., Teti A., Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research 2011 26 8 1891 1903 2-s2.0-79960623467 10.1002/jbmr.410
32. Evans N. P., Misyak S. A., Robertson J. L., Bassaganya-Riera J., Grange R. W., Immune-mediated mechanisms potentially regulate the disease time-course of Duchenne muscular dystrophy and provide targets for therapeutic intervention. Physical Medicine and Rehabilitation 2009 1 8 755 768 2-s2.0-68949143544 10.1016/j.pmrj.2009.04.010
33. Messina S., Vita G. L., Aguennouz M., Sframeli M., Romeo S., Rodolico C., Vita G., Activation of NF- B pathway in Duchenne muscular dystrophy: relation to age. Acta Myologica 2011 30 16 23 2-s2.0-79958072264
34. Kostek M. C., Nagaraju K., Pistilli E., IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskeletal Disorders 2012 13 106 10.1186/1471-2474-13-106
35. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M., The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology 2004 25 12 677 686 2-s2.0-7644231561 10.1016/j.it.2004.09. 015
36. Arnold L., Henry A., Poron F., Baba-Amer Y., Van Rooijen N., Plonquet A., Gherardi R. K., Chazaud B., Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. Journal of Experimental Medicine 2007 204 5 1057 1069 2-s2.0-34248997759 10.1084/jem.20070075
37. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A., IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology 1991 147 11 3815 3822 2-s2.0-0025889028
38. Villalta S. A., Rinaldi C., Deng B., Liu G., Fedor B., Tidball J. G., Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Human Molecular Genetics 2011 20 4 790 805 2-s2.0-78751682676 10.1093/hmg/ddq523
39. Furmanczyk P. S., Quinn L. S., Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell Biology International 2003 27 10 845 851 2-s2.0-0141788640 10.1016/S1065-6995(03)00172-0
40. Harcourt L. J., Holmes A. G., Gregorevic P., Schertzer J. D., Stupka N., Lynch G. S., Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. American Journal of Pathology 2005 166 4 1131 1141 2-s2.0-17144397257
41. Waite J. C., Skokos D., Th17 response and inflammatory autoimmune diseases. International Journal of Inflammation 2012 2012 10 10.1155/2012/819467 819467
42. De Pasquale L., D'Amico A., Verardo M., Petrini S., Bertini E., De Benedetti F., Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology 2012 78 17 1309 1314
43. Villalta S. A., Nguyen H. X., Deng B., Gotoh T., Tidbal J. G., Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Human Molecular Genetics 2009 18 3 482 496 2-s2.0-58749098598 10.1093/hmg/ddn376
44. Villalta S. A., Deng B., Rinaldi C., Wehling-Henricks M., Tidball J. G., IFN- γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. Journal of Immunology 2011 187 10 5419 5428 2-s2.0-81455154927 10.4049/jimmunol.1101267
45. Blobe G. C., Schiemann W. P., Lodish H. F., Role of transforming growth factor β in human disease. The New England Journal of Medicine 2000 342 18 1350 1358 2-s2.0-0034604110 10.1056/NEJM200005043421807
46. Passerini L., Bernasconi P., Baggi F., Confalonieri P., Cozzi F., Cornelio F., Mantegazza R., Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscular Disorders 2002 12 9 828 835 2-s2.0-0036837421 10.1016/S0960-8966(02)00071-8
47. Bernasconi P., Torchiana E., Confalonieri P., Brugnoni R., Barresi R., Mora M., Cornelio F., Morandi L., Mantegazza R., Expression of transforming growth factor- β 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. Journal of Clinical Investigation 1995 96 2 1137 1144 2-s2.0-0029153067
48. Zanotti S., Gibertini S., Mora M., Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF- β 1 treatment. Cell and Tissue Research 2010 339 2 397 410 2-s2.0-77949269532 10.1007/s00441-009-0889-4
49. Flanigan K. M., Ceco E., Lamar K. M., LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Annals of Neurology 2013 73 4 481 488
50. Wagner K. R., McPherron A. C., Winik N., Lee S.-J., Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Annals of Neurology 2002 52 6 832 836 2-s2.0-0036895736 10.1002/ana.10385
51. Chen Y.-W., Nagaraju K., Bakay M., McIntyre O., Rawat R., Shi R., Hoffman E. P., Early onset of inflammation and later involvement of TGF β in Duchenne muscular dystrophy. Neurology 2005 65 6 826 834 2-s2.0-25444505994 10.1212/01.wnl.0000173836.09176.c4
52. Locati M., Murphy P. M., Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annual Review of Medicine 1999 50 425 440 2-s2.0-0033051750 10.1146/annurev.med.50.1.425
53. Yogo Y., Fujishima S., Inoue T., Saito F., Shiomi T., Yamaguchi K., Ishizaka A., Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respiratory Research 2009 10, article no. 80 2-s2.0-77955487599 10.1186/1465-9921-10-80
54. De Paepe B., Creus K. K., Martin J. J., De Bleecker J. L., Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. Muscle & Nerve 2012 46 6 917 925
55. Pescatori M., Broccolini A., Minetti C., Bertini E., Bruno C., D'Amico A., Bernardini C., Mirabella M., Silvestri G., Giglio V., Modoni A., Pedemonte M., Tasca G., Galluzzi G., Mercuri E., Tonali P. A., Ricci E., Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB Journal 2007 21 4 1210 1226 2-s2.0-33947655852 10.1096/fj.06-7285com
56. Abdel-Salam E., Ehsan Abdel-Meguid I., Shatla R., Korraa S. S., Stromal cell-derived factors in Duchenne muscular dystrophy. Acta Myologica 2010 29 3 398 403 2-s2.0-79955762802
57. Porter J. D., Guo W., Merriam A. P., Khanna S., Cheng G., Zhou X., Andrade F. H., Richmonds C., Kaminski H. J., Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscular Disorders 2003 13 3 223 235 2-s2.0-0037373615 10.1016/s0960-8966(02)00242-0
58. Demoule A., Divangahi M., Danialou G., Gvozdic D., Larkin G., Bao W., Petrof B. J., Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm. American Journal of Respiratory Cell and Molecular Biology 2005 33 2 178 185 2-s2.0-24344452615 10.1165/rcmb.2004-0347OC
59. Mercuri E., Muntoni F., Muscular dystrophies. The Lancet 2013 381 9869 845 860
60. Gallardo E., Rojas-García R., De Luna N., Pou A., Brown R. H. Jr., Illa I., Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001 57 11 2136 2138 2-s2.0-0035846620
61. De Paepe B., Creus K. K., De Bleecker J. L., Chemokines in idiopathic inflammatory myopathies. Frontiers in Bioscience 2008 13 7 2548 2577 2-s2.0-38449097099 10.2741/2866
62. Baird G. S., Montine T. J., Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Archives of Pathology & Laboratory Medicine 2008 132 2 232 238 2-s2.0-38949171708
63. Van Putten M., Aartsma-Rus A., Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. Expert Opinion on Biological Therapy 2011 11 8 1025 1037 2-s2.0-79959889417 10.1517/14712598. 2011.579098
64. Van Deutekom J. C., Janson A. A., Ginjaar I. B., Frankhuizen W. S., Aartsma-Rus A., Bremmer-Bout M., Den Dunnen J. T., Koop K., Van Der Kooi A. J., Goemans N. M., De Kimpe S. J., Ekhart P. F., Venneker E. H., Platenburg G. J., Verschuuren J. J., Van Ommen G.-J. B., Local dystrophin restoration with antisense oligonucleotide PRO051. The New England Journal of Medicine 2007 357 26 2677 2686 2-s2.0-37549034298 10.1056/NEJMoa073108
65. Muntoni F., Wells D., Genetic treatments in muscular dystrophies. Current Opinion in Neurology 2007 20 5 590 594 2-s2.0-34648854432 10.1097/WCO. 0b013e3282efc157
66. Mendell J. R., Campbell K., Rodino-Klapac L., Sahenk Z., Shilling C., Lewis S., Bowles D., Gray S., Li C., Galloway G., Malik V., Coley B., Clark K. R., Li J., Xiao X., Samulski J., McPhee S. W., Samulski R. J., Walker C. M., Dystrophin immunity in Duchenne's muscular dystrophy. The New England Journal of Medicine 2010 363 15 1429 1437 2-s2.0-77957725001 10.1056/NEJMoa1000228
67. Flanigan K. M., Campbell K., Viollet L., Anti-dystrophin T-cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Human Gene Therapy Methods 2013 10.1089/hgtb.2013.092
68. Wong B. L. Y., Christopher C., Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Journal of Child Neurology 2002 17 3 183 190 2-s2.0-0036018879
69. Grounds M. D., Torrisi J., Anti-TNF α (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB Journal 2004 18 6 676 682 2-s2.0-1842454966 10.1096/fj.03-1024com
70. Gosselin L. E., Martinez D. A., Impact of TNF- α blockade on TGF- β 1 and type I collagen mRNA expression in dystrophic muscle. Muscle and Nerve 2004 30 2 244 246 2-s2.0-3242776169 10.1002/mus.20056
71. Hodgetts S., Radley H., Davies M., Grounds M. D., Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF α function with Etanercept in mdx mice. Neuromuscular Disorders 2006 16 9-10 591 602 2-s2.0-33748519220 10.1016/j.nmd.2006.06.011
72. Wells T. N. C., Power C. A., Shaw J. P., Proudfoot A. E. I., Chemokine blockers-therapeutics in the making? Trends in Pharmacological Sciences 2006 27 1 41 47 2-s2.0-30344488431 10.1016/j.tips.2005.11.001
73. Tidball J. G., Wehling-Henricks M., Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. Journal of Physiology 2007 578 1 327 336 2-s2.0-33845785972 10.1113/jphysiol.2006.118265
74. Yahiaoui L., Gvozdic D., Danialou G., Mack M., Petrof B. J., CC family chemokines directly regulate myoblast responses to skeletal muscle injury. Journal of Physiology 2008 586 16 3991 4004 2-s2.0-50049089622 10.1113/jphysiol.2008.152090
75. Warren G. L., Hulderman T., Mishra D., Gao X., Millecchia L., O'Farrell L., Kuziel W. A., Simeonova P. P., Chemokine receptor CCR2 involvement in skeletal muscle regeneration. FASEB Journal 2005 19 3 413 415 2-s2.0-14644430904 10.1096/fj.04-2421fje
76. Van Erp C., Irwin N. G., Hoey A. J., Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle & Nerve 2006 34 3 327 334 2-s2.0-33748078489 10.1002/mus.20590
77. Taniguti A. P. T., Pertille A., Matsumura C. Y., Neto H. S., Marques M. J., Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF- β 1 blocker. Muscle & Nerve 2011 43 1 82 87 2-s2.0-78650501005 10.1002/mus.21869
78. Andreetta F., Bernasconi P., Baggi F., Ferro P., Oliva L., Arnoldi E., Cornelio F., Mantegazza R., Confalonieri P., Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. Journal of Neuroimmunology 2006 175 1-2 77 86 2-s2.0-33746318677 10.1016/j.jneuroim.2006. 03.005
79. Bogdanovich S., Krag T. O. B., Barton E. R., Morris L. D., Whittemore L.-A., Ahima R. S., Khurana T. S., Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002 420 6914 418 421 2-s2.0-0037191752 10.1038/nature01154
80. Morine K. J., Bish L. T., Selsby J. T., Gazzara J. A., Pendrak K., Sleeper M. M., Barton E. R., Lee S.-J., Sweeney H. L., Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle & Nerve 2010 42 5 722 730 2-s2.0-78149299780 10.1002/mus.21743
81. Qiao C., Li J., Jiang J., Zhu X., Wang B., Li J., Xiao X., Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Human Gene Therapy 2008 19 3 241 253 2-s2.0-41149152962 10.1089/hum.2007.159
82. Zanotti S., Gilbertini S., Salvadori P., Mantegazza R., Mora M., Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents. Cell and Tissue Research 2013 353 3 659 670
83. Louvet A., Teixeira-Clerc F., Chobert M.-N., Deveaux V., Pavoine C., Zimmer A., Pecker F., Mallat A., Lotersztajn S., Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2011 54 4 1217 1226 2-s2.0-80053314254 10.1002/hep.24524
84. Hussein M. R., Hamed S. A., Mostafa M. G., Abu-Dief E. E., Kamel N. F., Kandil M. R., The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. International Journal of Experimental Pathology 2006 87 6 451 461 2-s2.0-33751384791 10.1111/j.1365-2613.2006.00470.x